You are here: Industry Insights > Otsuka

News List

Otsuka and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder pharmafocusasia
January 07, 2019
Otsuka America, Inc., and Click Therapeutics, Inc., announce today that the companies have signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for .....
Otsuka’s guadecitabine fails phase 3 AML trial fiercebiotech
August 01, 2018
Otsuka’s guadecitabine has missed its coprimary endpoints in a phase 3 acute myeloid leukemia (AML) trial. The DNA hypomethylating agent failed to beat the complete response or overall survival rates achieved in the control arm.....
Otsuka snaps up Visterra in $430 million deal pharmafile
July 17, 2018
Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an all-cash transaction to the value of $430 million.
Otsuka's Jynarque garners FDA approval for autosomal dominant polycystic kidney disease firstwordpharma
April 26, 2018
Otsuka Pharmaceutical announced that U.S. Food and Drug Administration approves Jynarque (tolvaptan) as the first drug treatment plan in the United States
Claris completes sale of its stake in JV to Otsuka expressbpd
September 26, 2017
Claris Lifesciences has recently completed the sale of its remaining 20 per cent stake in Otsuka Pharmaceutical India
Otsuka, Mylan to Commercialize Delamanid americanpharmaceuticalreview
August 25, 2017
Otsuka Pharmaceutical and Mylan have entered into a license agreement between their subsidiaries to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries
Claris sells stake to Otsuka for $20 m biospectrumasia
May 11, 2017
Otsuka now owns 80% of the joint venture, earlier known as Claris Otsuka Pvt. Ltd, while Mitsui continues to hold 20%.

Previous page 1 2 Next page